B. B. 莱利将管弦乐团BioMed升级为“强购”,目标为15美元,尽管财政困难。 B. Riley upgrades Orchestra BioMed to "strong-buy," targeting $15 despite financial challenges.

B. B. Riley将管弦乐队BioMed(OBIO)升级为“强购”评级,共识为“Buy”和15美元价格目标。 B. Riley upgraded Orchestra BioMed (OBIO) to a "strong-buy" rating, with a consensus "Buy" and a $15 price target. 尽管股票和净利润出现负回报,但该公司侧重于生物医学创新,如高血压心脏神经调节和动脉疾病治疗气球等。 Despite a negative return on equity and net margin, the company focuses on biomedical innovations like cardiac neuromodulation for hypertension and a balloon for artery disease treatment. 股票的市场上限为104.92亿美元,星期四营业额为2.76美元,在1年的2.65美元至8.87美元之间。 The stock, with a market cap of $104.92M, opened at $2.76 on Thursday, within a 1-year range of $2.65 to $8.87.